Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia

Cerebrospinal fluid (CSF) samples from 33 patients with Alzheimer dementia (AD), 21 patients with mild cognitive impairment who converted to AD during followup (MCI-AD), 25 patients with stable mild cognitive impairment (MCI-stable), and 16 nondemented subjects (ND) were analyzed with a chemiluminescence immunoassay to assess the levels of the mitogen-activated protein kinase ERK1/2 (extracellular signal-regulated kinase 1/2). The results were evaluated in relation to total Tau (tTau), phosphorylated Tau (pTau), and beta-amyloid 42 peptide (Aβ42). CSF-ERK1/2 was significantly increased in the AD group as compared to stable MCI patients and the ND group. Western blot analysis of a pooled cerebrospinal fluid sample revealed that both isoforms, ERK1 and ERK2, and low amounts of doubly phosphorylated ERK2 were detectable. As a predictive diagnostic AD biomarker, CSF-ERK1/2 was inferior to tTau, pTau, and Aβ42.

[1]  Xiaojing Sui,et al.  Cerebrospinal fluid biomarkers of Alzheimer’s disease , 2014, Neuroscience Bulletin.

[2]  K. Blennow,et al.  cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases , 2010, International journal of Alzheimer's disease.

[3]  Hilkka Soininen,et al.  J-ADNI and selection of cognition measures , 2010, Alzheimer's & Dementia.

[4]  J. Fleming,et al.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking , 2009, Neurology.

[5]  L. Parnetti,et al.  Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting , 2009, TheScientificWorldJournal.

[6]  W. M. van der Flier,et al.  A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease , 2009, Annals of clinical biochemistry.

[7]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[8]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[9]  P. Lewczuk,et al.  Neurochemical dementia diagnostics: State of the art and research perspectives , 2008, Proteomics.

[10]  Hilkka Soininen,et al.  CSF Aβ42, Tau and phosphorylated Tau, APOE ɛ4 allele and MCI type in progressive MCI , 2007, Neurobiology of Aging.

[11]  Johannes Kornhuber,et al.  Therapeutic approaches to Alzheimer's disease. , 2006, Brain : a journal of neurology.

[12]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[13]  Lucilla Parnetti,et al.  Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers , 2006, Mechanisms of Ageing and Development.

[14]  R. Slack,et al.  Emerging Role for ERK as a Key Regulator of Neuronal Apoptosis , 2004, Science's STKE.

[15]  R. Nussbaum,et al.  Alzheimer's disease and Parkinson's disease. , 2003, The New England journal of medicine.

[16]  George Perry,et al.  The Role of Mitogen-Activated Protein Kinase Pathways in Alzheimer’s Disease , 2002, Neurosignals.

[17]  J. Sweatt,et al.  The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory , 2001, Journal of neurochemistry.

[18]  Patrick R. Hof,et al.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.

[19]  S. Grewal,et al.  Extracellular-signal-regulated kinase signalling in neurons , 1999, Current Opinion in Neurobiology.

[20]  E. Goldsmith,et al.  How MAP Kinases Are Regulated (*) , 1995, The Journal of Biological Chemistry.

[21]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[22]  H. W. Harris,et al.  Extracellular signal-regulated protein kinases (ERKs) and ERK kinase (MEK) in brain: regional distribution and regulation by chronic morphine , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  E Capitani,et al.  A neuropsychological instrument adding to the description of patients with suspected cortical dementia: the Milan overall dementia assessment. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[24]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[25]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[27]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[28]  R. Petersen,et al.  Cognitive Impairment : An Overview By , 2013 .

[29]  J. Wiltfang,et al.  ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. , 2010, Journal of Alzheimer's disease : JAD.

[30]  F. Jessen,et al.  Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form. , 2009, Journal of Alzheimer's disease : JAD.

[31]  Hilkka Soininen,et al.  CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. , 2007, Neurobiology of aging.

[32]  J. Sweatt,et al.  MAPK regulation of gene expression in the central nervous system. , 2000, Acta neurobiologiae experimentalis.

[33]  M Haupt,et al.  [Clinical diagnosis of Alzheimer's disease]. , 1988, Deutsche medizinische Wochenschrift.